274 Prevalence of anti-dfs70 antibodies in a colombian cohort: a case-control study

Arteaga, Stephanie; Urrego, Tomás; Peñaranda, LM; Londoño, A; Cardenas, ML; Vanegas-García, Adriana L.; Muñoz, CH; Escobar, Mauricio Restrepo; Rojas, Winston; Vásquez, Gloría; González, LA; Koller, Carl; Gόmez-Puerta, JA

doi:10.1136/lupus-2017-000215.274

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Colombia in 100 SLE patients, 102 SARD, and 200 HC, 56 subjects were suspected of having an autoimmune disease with ANA positive and negative anti dsDNA antibodies. ANA/DFS70 antibodies were positive in 1.8% of subjects with ANA positive/anti dsDNA negative, in 1% of SLE patients, 0.9% of patients with other SARD and only in 0.5% of HC [ 33 ]. A similar low frequency was found in our study with 2.3% but the frequency of ANA/DFS70 in other autoantibodies negative was just 0.5% (PsO patient).…”

Section: Discussionmentioning

confidence: 99%

Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia

et al. 2022

View full text Add to dashboard Cite

Background: The presence of Antinuclear antibodies/Dense Fine Speckled 70 (ANA/DFS70) has been proposed as a negative biomarker in the process of exclusion of systemic autoimmune/autoinflammatory rheumatic diseases (SARD). The purpose was to evaluate and characterize ANA/DFS70 patients in a large Colombian population with SARD; rheumatoid arthritis (RA), Psoriasis (PsO), Undifferentiated connective tissue disease (UCTD), first-degree relatives of (FDR), and healthy controls (HC). Methods: ANA determination was performed using indirect immunofluorescence. Samples with positive dense fine granular staining in the nucleoplasm of the interphase cell (AC2) fluorescence were confirmed with CytoBead/ANA and ANA/modified (Knocked out for the PSPI1 gen). Results: 530 mestizo Colombian participants were included. ANA/DFS70 antibody positivity in the whole group was 2.3%, and 0.8% in SARD; no RA patients were positive. ANA/DFS70 positives in UCTD were three women; the average time of evolution of the disease was 9.4 years. The most frequent clinical findings were arthralgias, non-erosive arthritis, and Raynaud’s phenomenon. The PsO positive was a woman with C-reactive protein (CRP) positivity and a negative erythrocyte sedimentation rate (ESR) without any other positive autoantibody or extracutaneous manifestation. FDR and HC positives were 7/8 women. All were negative for other autoantibodies. Conclusions: ANA/DFS70 autoantibodies were present in Colombian patients with SARD at a shallow frequency, they were more prevalent in healthy individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The presence of the anti-DFS70 antibody was initially documented in patients with different nonrheumatic inflammatory conditions and in apparently healthy individuals and was therefore associated with a low probability of CTD. In patients with CTD, anti-DSF70 antibody is usually accompanied by other specific autoantibodies such as anti-DNA and anti-Scl-70 (11)(12)(13)(14). The prevalence of ANA/DFS70 antibodies in a population with UCTD ranges from 8-40%, and it is considered a potential negative predictor for the risk of progressing from UCTD to CTD (12,15,16).…”

Section: Original Papermentioning

confidence: 99%

Frequency of ANA/DFS70 autoantibodies in Colombian patients with undifferentiated connective tissue disease

et al. 2022

View full text Add to dashboard Cite

The objective was to describe the clinical characteristics and the frequency of the ANA/DFS70 autoantibodies in patients affected by undifferentiated connective tissue disease (UCTD) in a tertiary hospital in Colombia. This descriptive cross-sectional study enrolled patients who fulfilled the classification criteria for UCTD. ANAHEp- 2 test and the modified assay for ANA/DFS70 autoantibodies were performed through the indirect immunofluorescence technique. Erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, and the antibodies to anti-extractable nuclear antigens, DNA, phospholipids (IgG, IgM, IgA), and cyclic citrullinated peptide were also evaluated. Fifty-three patients were studied; 42/53 (79%) tested positive for ANA and 5/42 (11.9%) for ANA/DFS70 antibodies with a dense fine speckled fluorescent pattern (AC-2) in ANA HEp-2 test that was confirmed by a modified HEp-2-DFS70 assay. Patients had arthralgia (87%, n=47), non-erosive arthritis (66%, n=34), xerostomia (64%, n=34), xerophthalmia (42%, n=22), and Raynaud’s phenomenon (17%, n=9). Arthralgia, xerophthalmia, xeroderma, and absence of disease evolution to a specific disease over five years were more frequent in patients with a positive result for the anti-DFS70 antibodies. The ANA/DFS70 autoantibodies were more frequent in patients with UCTD compared to other rheumatic diseases for which they were initially evaluated. More studies are required to support the predictive role of this antibody to the absence of progression to a well-defined connective tissue disease.

show abstract

“…[6], cancers (e.g., prostate cancer, breast cancer, etc.) [7,8] and healthy individuals (HI) [6, [9][10][11][12][13][14][15][16][17]. As an antinuclear autoantibody (ANA), most studies have focused on the clinical association between anti-DFS70 and systemic autoimmune rheumatic diseases (SARD) [6, 14,18], reporting that anti-DFS70 prevalence is comparable in SARD and in HI [19] unlike other autoantibodies which are common in different types of SARD.…”

Section: Introductionmentioning

confidence: 99%

Anti-DFS70 antibodies are more prevalent in UCTD and Asian SLE patients

Zhu,

Chu,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives Anti-dense-fine-speckled 70 (anti-DFS70) autoantibodies were reported to occur frequently in antinuclear autoantibody (ANA) positive healthy individuals (HI), but have also been detected in patients with systemic autoimmune rheumatic disease (SARD), and the prevalence varies between different SARD types. This study aimed to detect the prevalence of anti-DFS70 in different SARD patients in China and study the geographical differences of it by meta-analysis.Methods Anti-DFS70 antibodies were detected in 113 HI and 541 SARD patients, including 163 systemic lupus erythematosus (SLE), 99 rheumatoid arthritis (RA), 93 undifferentiated connective tissue disease (UCTD), 82 Sjogren's syndrome (SS), 55 polymyositis/dermatomyositis (PM/DM), 31 systemic sclerosis (SSc) and 18 mixed connective tissue disease (MCTD) patients by enzyme-linked immunosorbent assay. Pooled odds ratios (OR) and corresponding confidence intervals (CI) of the comparison anti-DFS70 prevalence in disease and control group were calculated by meta-analysis.Results Anti-DFS70 was higher in SLE (20.2%, P = 0.004) and UCTD (12.9%, P = 0.02) than in HI (7.1%) in China. No statistical differences with HI in RA (11.1%, P = 0.31), PM/DM (10.9%, P = 0.4), SS (7.3%, P = 0.95), SSc (3.2%, P = 0.44) and MCTD (0%, P = 0.46). The meta-analysis showed higher anti-DFS70 in Asian SLE patients than in HI (OR = 2.32, 95%CI = 1.54–3.49, P < 0.0001), while no difference was observed between non-Asian SLE and HI (OR = 0.38, 95%CI = 0.14–1.07, P > 0.05). Anti-DFS70 prevalence was higher in UCTD patients than in HI (OR = 2.38, 95%CI = 1.36–4.15, P = 0.002) without regional variation (Asian: OR = 2.35, 95%CI = 1.13–4.88, P = 0.02; non-Asian: OR = 2.43, 95%CI = 1.06–5.57, P = 0.04).Conclusions The prevalence of anti-DFS70 antibody varies among SLE patients in Asia and non-Asia. Contrarily, anti-DFS70 prevalence in UCTD cohort is higher than in HI worldwide.

show abstract

274 Prevalence of anti-dfs70 antibodies in a colombian cohort: a case-control study

Cited by 3 publications

References 0 publications

Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia

Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia

Frequency of ANA/DFS70 autoantibodies in Colombian patients with undifferentiated connective tissue disease

Anti-DFS70 antibodies are more prevalent in UCTD and Asian SLE patients

Contact Info

Product

Resources

About